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Figure 1. Photomicrographs of specimens from a lytic lesion of the right tibia demonstrating Histoplasma capsulatum var. duboisii. Left, periodic
acid-Schiff staining reveals a thick cell wall, vacuolated cytoplasm, and narrow-based bud. Right, Grocott methenamine silver staining demonstrates
the classic “hour-glass” shape of H. capsulatum var. duboisii; the parent and daughter cells are of equal size and joined by a narrow base.
Accurate Diagnosis of
Infection with Histoplasma
capsulatum var. duboisii
Sir—Although the image of the skin bi-
opsy specimen in the recent photo quiz
by Hasse and Kronenberg [1] may rep-
resent infection with Histoplasma capsu-
latum var. duboisii, it does not prove the
diagnosis. The fungus was apparently not
cultured, and the photomicrograph of the
organisms shows nothing specifically di-
agnostic of H. capsulatum var. duboisii.
The photomicrograph of the skin speci-
men stained with periodic acid-Schiff stain
reveals clusters of yeast that appear more
round than oval and do not show the
“hour-glass” or “figure eight” budding
forms typical of H. capsulatum var. du-
boisii [2]. Chain formation and bud scars
are 2 other features of this organism (fig-
ure 1); neither is demonstrated in the im-
age provided by Hasse and Kronenberg
[1].
Cryptococcus neoformans may vary in
size by as much as 20 microns, and the
capsular-deficient form can appear similar
to the image seen in the figure provided
by Hasse and Kronenberg [1]; a positive
reaction with mucicarmine stain would be
diagnostic. Blastomyces dermatitis is a sim-
ilar size and also has a thick cell wall; di-
agnosis requires identification of broad-
based buds and/or multiple nuclei.
Blastomycosis is not likely in a patient
from Africa or Europe.
Mary Klassen-Fischer, Peter McEvoy,
Ronald C. Neafie, and Ann Marie Nelson
Department of Infectious and Parasitic Diseases
Pathology, Armed Forces Institute of Pathology,
Washington, D.C.
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Reply
Sir—We appreciate the comments of
Klassen et al. [1]. We agree that the find-
ings of histologic examination of the skin
biopsy specimen alone are congruent with
but do not prove the diagnosis of infection
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with Histoplasma capsulatum var. duboisii.
However, as we mentioned in the case de-
scription, we were able to cultivate H. cap-
sulatum var. duboisii from a specimen of
a relapsing skin lesion obtained 2 months
after the patient had stopped taking his
medication by his own decision. Further-
more, the clinical presentation was very
typical for African histoplasmosis. As you
mention, Blastomyces dermatitis infection
is unlikely in an African patient. Crypto-
coccus neoformans infection could be ex-
cluded if a crytpococcal antigen test
yielded a negative result.
Barbara Hasse and Andreas Kronenberg
Division of Infectious Diseases and Hospital
Epidemiology, University Hospital,
Zurich, Switzerland
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Hypothyroidism in
HIV-Infected Patients
Who Have or Have Not
Received HAART
Sir—Beltran et al. [1] recently reported an
increase in the prevalence of subclinical
hypothyroidism among HIV-infected pa-
tients, compared with the general popu-
lation. This difference was particularly rel-
evant for male patients. Moreover, the
authors reported a statistically significant
relationship between subclinical hypothy-
roidism, receipt of therapy containing sta-
vudine, and the degree of immunodefi-
ciency of the patients [1].
To assess the prevalence of subclinical
hypothyroidism among HIV-infected pa-
tients and to identify the associated risk
factors, we performed a retrospective
analysis of HIV-infected patients who were
untreated or who were receiving highly
active antiretroviral therapy (HAART).
The patients had been observed at 6 de-
partments of infectious diseases and had
total thyroxine and thyroid-stimulating
hormone levels measured during the pe-
riod of January 2000 through December
2002. Thyroid function had generally been
assessed during routine testing or as part
of the screening examinations performed
before treatment of hepatitis C virus
(HCV) coinfection and chronic hepatitis.
None of these patients had any symptoms
of altered thyroid function.
We investigated 687 patients observed
in 6 infectious diseases departments be-
longing to the Coordinamento Italiano
Studio Allergia e Infezione da HIV group.
A total of 446 patients (65%) were men,
and the mean age (SD) was 40.5
years. The mean CD4+ lymphocyte8.5
count (SD) when the thyroid function
was checked was 469  267 cells/mm3.
Three hundred thirty-two patients
(48.3%) tested positive for HCV antibody,
none of whom were receiving IFN therapy
at the time. Fifty-nine patients were naive
to antiretroviral therapy, and 628 were re-
ceiving HAART.
In 51 patients (7.42%), we detected
subclinical hypothyroidism; 5 (9.8%) of
these patients were treatment naive, and
46 (90.2%) were receiving antiretroviral
therapy. The frequency of this disease
among male subjects was 7.11%, which
was slightly lower than the frequency
among female subjects (8.71%). The re-
sults of tests for antithyroglobulin anti-
body and thyroid antimicrosomes per-
formed for 270 cases were negative.
To assess risk factors, we considered the
following covariates: age, sex, stage and
duration of infection, CD4+ lymphocyte
count when thyroid function was tested,
positive results of tests for HCV antibody,
and, in patients receiving HAART, total
duration of HAART and of treatment with
protease inhibitors. Statistical differences
between general and clinical characteris-
tics were analyzed using the x2 test, com-
paring observed and expected events. ORs,
as estimators of relative risks, were com-
puted using unconditional multiple logis-
tic regression.
None of the variables considered were
significantly related to the onset of sub-
clinical hypothyroidism. In particular, we
did not find a statistically significant re-
lationship between subclinical hypothy-
roidism and any drug or the degree of
immunodeficiency.
The results from our study confirm the
data on the prevalence of subclinical hy-
pothyroidism reported by Beltran et al. [1]
and others [2, 3]. Our results also confirm
that the prevalence of this condition is
higher among male subjects, compared
with men in the general population. In our
cohort, we noted subclinical hypothyroid-
ism in both treatment-naive and HAART-
treated patients with a similar prevalence.
In contrast with the findings of Beltran et
al. [1], we found no clear risk factors in
HAART-receiving subjects that were re-
lated to the occurrence of subclinical
hypothyroidism.
Our data, if confirmed in a prospective
study, might raise issues regarding the
pathogenesis of subclinical hypothyroid-
ism as it relates to HIV infection itself.
However, it appears to be important to
periodically assess thyroid function in
HIV-infected patients, especially in view
of the possibility that subclinical hypothy-
roidism might be a risk factor for cardio-
vascular disease [4].
T. Quirino,1 M. Bongiovanni,1 E. Ricci,3
E. Chebat,2 S. Carradori,4 C. Martinelli,5
L. Valsecchi,1 S. Landonio,1 T. Bini,1
and P. Bonfanti,1 for the Coordinamento
Italiano Studio Allergia e Infezione da HIV
(CISAI) Group
Departments of 1Infectious Diseases and
2Endocrinology, L Sacco Hospital, and 3Istituto di
Ricerche Farmacologiche “Mario Negri,” Milan,
4Department of Infectious Diseases, S. Anna
Hospital, Ferrara, and 5Department of Infectious
Diseases, Careggi Hospital, Florence, Italy
References
1. Beltran S, Lescure FX, Desailloud R, et al. In-
creased prevalence of hypothyroidism among
human immunodeficiency virus–infected pa-
tients: a need for screening. Clin Infect Dis
2003; 37:579–83.
